ADMP - Adamis Pharmaceuticals Corporation
| Previous Close | 3.45 |
| Open | 3.45 |
| Bid | 3.15 x 800 |
| Ask | 3.20 x 900 |
| Day's Range | 3.17 - 3.45 |
| 52 Week Range | 2.35 - 5.85 |
| Volume | 348,707 |
| Avg. Volume | 447,526 |
| Market Cap | 107.901M |
| Beta | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.88 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.41 |
- Zacks•24 days ago
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
- Zacks•last month
Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
- Associated Press•2 months ago
Adamis: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 23 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
- GlobeNewswire•2 months ago
Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, said, “We have made a substantial amount of progress on several fronts since the beginning of the year. The development of our product pipeline continues to move forward and we have several target milestones that we hope to reach later this year. We believe the completion of these milestones will increase shareholder value. Symjepi ™ (epinephrine) Injection 0.15mg – The FDA determined that the company’s NDA for Symjepi ™ (epinephrine) Injection 0.15mg was sufficiently complete to permit a substantive review and indicated that no potential review issues were identified as of the date of the agency’s communication in February. Approval is expected in the second half of this year.
- Zacks•2 months ago
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
Investors in Adamis Pharmaceuticals (ADMP) need to pay close attention to the stock based on moves in the options market lately.
- Simply Wall St.•2 months ago
High Growth Stocks To Invest In
Robust, high-growth companies such as Adamis Pharmaceuticals are appealing to investors for many reasons. They bring about a strong upside to your portfolio, and less downside risk as opposed toRead More...
- GlobeNewswire•2 months ago
Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•2 months ago
What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)
Adamis Pharmaceuticals (ADMP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
- Capital Cube•6 months ago
ETFs with exposure to Adamis Pharmaceuticals Corp. : December 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Adamis Pharmaceuticals Corp. Here are 5 ETFs with the largest exposure to ADMP-US. Comparing the performance and risk of Adamis Pharmaceuticals Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- ACCESSWIRE•7 months ago
Today’s Research Reports on Stocks to Watch: Revance Therapeutics and Adamis Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 6, 2017 / Shares of Revance headed higher on Tuesday after announcing successful results in a pair of phase 3 clinical trials that are evaluating its RT002 treatment ...
- SmarterAnalyst•7 months ago
Raymond James Sings the Praises of Adamis Pharmaceuticals; Here’s Why
What does the future hold for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)? Raymond James analyst Elliot Wilbur is out today with a bullish note on the specialty biopharmaceutical company, after the latter announced that it has submitted an IND to test naloxone in human patients using Symject, presumably as a reaction to the worsening opioid crisis.
- SmarterAnalyst•7 months ago
Adamis Pharmaceuticals Corp (ADMP) Moves Forward with a New Opioid Overdose Drug
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin testing the drug compound naloxone in human patients. Adamis intends to develop a naloxone injection product candidate utilizing the same patented SymjectTM syringe drug delivery platform used in Adamis’ approved SymjepiTM product, which is an epinephrine injection drug/device combination for the emergency treatment of acute allergic reactions including anaphylaxis. Naloxone is an opioid antagonist used to treat narcotic overdoses. Naloxone, which is generally considered the drug of choice for immediate administration for opioid overdose, blocks or reverses the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl.
- SmarterAnalyst•7 months ago
This Bull Cheers for Adamis Pharmaceuticals Following PAS Submission for Pediatric Version of Epinephrine Auto-Injector Symjepi
Adamis Pharmaceuticals (NASDAQ:ADMP) investors sent the stock on a nearly 9% gain in value yesterday on back of the news of the company's submission to the FDA of a prior approval supplement (PAS) for the pediatric version of Symjepi. With the pediatric version designed differently than the original, FBR analyst Andrew D'silva actually sees less risk circling a potential approval on ADMP's allergy shot than the original version of the epinephrine auto-injector, a cheaper option to competitor Mylan's EpiPen.
